CY2023020I2 - Συνθεσεις mycoplasma bovis - Google Patents

Συνθεσεις mycoplasma bovis

Info

Publication number
CY2023020I2
CY2023020I2 CY2023020C CY2023020C CY2023020I2 CY 2023020 I2 CY2023020 I2 CY 2023020I2 CY 2023020 C CY2023020 C CY 2023020C CY 2023020 C CY2023020 C CY 2023020C CY 2023020 I2 CY2023020 I2 CY 2023020I2
Authority
CY
Cyprus
Prior art keywords
compositions
mycoplasma bovis
bovis
mycoplasma
bovis compositions
Prior art date
Application number
CY2023020C
Other languages
English (en)
Other versions
CY2023020I1 (el
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of CY2023020I2 publication Critical patent/CY2023020I2/el
Publication of CY2023020I1 publication Critical patent/CY2023020I1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/35—Mycoplasma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CY2023020C 2015-08-14 2023-10-03 Συνθεσεις mycoplasma bovis CY2023020I1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562205125P 2015-08-14 2015-08-14
PCT/US2016/046572 WO2017030901A1 (en) 2015-08-14 2016-08-11 Mycoplasma bovis compositions

Publications (2)

Publication Number Publication Date
CY2023020I2 true CY2023020I2 (el) 2024-02-16
CY2023020I1 CY2023020I1 (el) 2024-02-16

Family

ID=56800367

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20221100762T CY1125699T1 (el) 2015-08-14 2022-12-02 Συνθεσεις mycoplasma bovis
CY2023020C CY2023020I1 (el) 2015-08-14 2023-10-03 Συνθεσεις mycoplasma bovis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20221100762T CY1125699T1 (el) 2015-08-14 2022-12-02 Συνθεσεις mycoplasma bovis

Country Status (23)

Country Link
US (2) US11389518B2 (el)
EP (2) EP4137152A1 (el)
JP (1) JP6675484B2 (el)
CN (3) CN108135989B (el)
AU (2) AU2016307935B2 (el)
BR (1) BR112018002919B1 (el)
CA (1) CA2995101A1 (el)
CY (2) CY1125699T1 (el)
DK (1) DK3334454T3 (el)
ES (1) ES2933623T3 (el)
FI (1) FI3334454T3 (el)
FR (1) FR23C1037I2 (el)
HR (1) HRP20221440T1 (el)
HU (2) HUE060545T2 (el)
LT (2) LT3334454T (el)
LU (1) LUC00319I2 (el)
MX (1) MX389685B (el)
NL (1) NL301244I2 (el)
PL (1) PL3334454T3 (el)
PT (1) PT3334454T (el)
SI (1) SI3334454T1 (el)
WO (1) WO2017030901A1 (el)
ZA (1) ZA201800956B (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109022314B (zh) * 2018-08-06 2021-08-13 北京华夏兴洋生物科技有限公司 一株牛支原体及其在疫苗研制中的应用
CN111471695A (zh) * 2020-05-11 2020-07-31 吉林农业大学 牛支原体免疫磁珠的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
DE69233158T2 (de) 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
WO1993013302A1 (de) 1991-12-23 1993-07-08 Michael Zoche Motor mit einer vorrichtung zur entölung
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
JP2000507092A (ja) 1996-02-28 2000-06-13 バイエル・アクチエンゲゼルシヤフト 外来ｄｎａを含むパラポックスウイルス、それらの製造及びワクチンにおけるそれらの使用
AU729579B2 (en) 1996-10-23 2001-02-01 Trustees Of The University Of Pennsylvania, The Immunotherapy and improved vaccines
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
ATE512231T1 (de) 1998-02-27 2011-06-15 Univ Pennsylvania Impfstoffe, immuntherapeutika und verfahren zur anwendung derselben
PT1061955E (pt) 1998-03-13 2005-08-31 Wyeth Corp Composicao de polinucleotido, metodo de preparacao e sua utilizacao
PT1117435E (pt) 1998-09-30 2008-02-21 Us Gov Univ Health Sciences Holotoxina da cólera mutante como adjuvante
BR0015398A (pt) 1999-11-08 2002-06-25 Biomune Vacinas para mycoplasma bovis e processos de uso
US6548069B2 (en) 2001-02-03 2003-04-15 Hmv Associates, Inc. Multivalent Mycoplasma bacterin
GB0110851D0 (en) 2001-05-03 2001-06-27 Mini Agriculture & Fisheries Vaccine
AU2002346249B2 (en) 2001-06-07 2007-03-15 The Regents Of The University Of Colorado Mutant Forms of Cholera Holotoxin as an Adjuvant
US7332174B2 (en) 2001-06-07 2008-02-19 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
US20030147914A1 (en) 2001-07-02 2003-08-07 Pfizer Inc. Mycoplasma bovis vaccine and methods of reducing pneumonia in animals
EP2363493B1 (en) 2003-02-20 2012-11-14 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Novel insertion sites in pox vectors
US20090068231A1 (en) * 2007-09-11 2009-03-12 Wyeth Live attenuated mycoplasma strains
AR069087A1 (es) * 2007-10-29 2009-12-30 Boehringer Ingelheim Vetmed Cepa bacteriana de m. bovis atenuada avirulenta obtenida por pases, vacuna de micoplasma boris y metodos de uso de la misma
EP2320943B1 (en) 2008-07-03 2016-02-17 Iowa State University Research Foundation, Inc. Cattle vaccines
MX2011004316A (es) * 2008-10-31 2011-06-16 Boehringer Ingelheim Vetmed Uso de antigenos diversos que incluyen antigenos de mycoplasma bovis en composicion de vacuna multivalente.
US20120045475A1 (en) * 2009-02-20 2012-02-23 Australian Poultry Crc Pty Limited Live attenuated vaccines
UY32570A (es) 2009-04-24 2010-11-30 Boehringer Ingelheim Vetmed Vacuna viva modificada de mycoplasma bovis mejorada

Also Published As

Publication number Publication date
HUE060545T2 (hu) 2023-03-28
JP2018523708A (ja) 2018-08-23
US20220296694A1 (en) 2022-09-22
BR112018002919B1 (pt) 2024-02-27
WO2017030901A1 (en) 2017-02-23
SI3334454T1 (sl) 2023-02-28
EP3334454B1 (en) 2022-10-19
FI3334454T3 (fi) 2023-01-13
EP4137152A1 (en) 2023-02-22
CN115141772A (zh) 2022-10-04
CN108135989B (zh) 2022-08-09
AU2016307935A1 (en) 2018-02-22
PT3334454T (pt) 2022-12-20
HK1251478A1 (en) 2019-02-01
CY1125699T1 (el) 2024-02-16
NZ778923A (en) 2025-05-02
US20190255166A1 (en) 2019-08-22
HRP20221440T1 (hr) 2023-02-03
LT3334454T (lt) 2022-12-27
BR112018002919A2 (pt) 2018-09-18
EP3334454A1 (en) 2018-06-20
HUS2300032I1 (hu) 2024-07-28
AU2022231761B2 (en) 2025-09-18
NL301244I2 (nl) 2023-11-01
NL301244I1 (nl) 2023-10-04
MX389685B (es) 2025-03-20
DK3334454T3 (da) 2022-11-14
CA2995101A1 (en) 2017-02-23
CN115141773A (zh) 2022-10-04
US11389518B2 (en) 2022-07-19
ZA201800956B (en) 2018-12-19
PL3334454T3 (pl) 2023-01-30
LUC00319I2 (el) 2026-02-02
NZ739767A (en) 2025-05-02
LTPA2026509I1 (el) 2026-03-25
CN108135989A (zh) 2018-06-08
AU2016307935B2 (en) 2022-08-18
JP6675484B2 (ja) 2020-04-01
FR23C1037I1 (fr) 2023-12-08
FR23C1037I2 (fr) 2025-12-19
CY2023020I1 (el) 2024-02-16
AU2022231761A1 (en) 2022-10-06
ES2933623T3 (es) 2023-02-10
MX2018001841A (es) 2018-08-01

Similar Documents

Publication Publication Date Title
EP3534968A4 (en) ANTI-BCMA T CAR LYMPHOCYTE COMPOSITIONS
DK3361870T3 (da) Fungicidsammensætninger
PT3380108T (pt) Composições bacterianas concebidas
MA41976A (fr) Composition lubrifiante ultra-fluide
DK3542812T3 (da) Glycopeptidsammensætninger
EP3339331A4 (en) COMPOSITION
EP3398996A4 (en) COMPOSITION
DK3250182T3 (da) Dispergible sammensætninger
DK3334726T3 (da) Plinabulinsammensætninger
EP3385358A4 (en) LUBRICANT COMPOSITION
FR3034100B1 (fr) Composition lubrifiante
EP3395887C0 (en) FLUOROR RUBBER COMPOSITION
DK3322295T3 (da) Sammensætning
DK3316857T3 (da) Multifasiske sammensætninger
DK3528791T3 (da) Dispergible sammensætninger
CY2023020I1 (el) Συνθεσεις mycoplasma bovis
DK3393254T3 (da) Sammensætning
LT3173071T (lt) Maropitanto kompozicija
EP3369418A4 (en) COMPOSITION
HUE054061T2 (hu) Viszko-elasztikus összetétel
EP3344737C0 (en) LUBRICATING COMPOSITION
DK3347444T3 (da) Fedtsammensætninger
BR112017016240A2 (pt) composição
DK3200827T3 (da) Sammensætninger
LT3359185T (lt) Priešnavikinė kompozicija